Dr. Davids on the Combination of Ibrutinib and Obinutuzumab in CLL

Matthew S. Davids, MD, MMSc
Published: Tuesday, Jan 02, 2018



Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

For patients with relapsed/refractory CLL, ibrutinib is the current standard therapy. There are many combination studies investigating ibrutinib plus obinutuzumab, explains Davids. In a phase Ib study, investigators are determining if the order of administration of ibrutinib and obinutuzumab affects the safety and the efficacy of the combination.
 


Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

For patients with relapsed/refractory CLL, ibrutinib is the current standard therapy. There are many combination studies investigating ibrutinib plus obinutuzumab, explains Davids. In a phase Ib study, investigators are determining if the order of administration of ibrutinib and obinutuzumab affects the safety and the efficacy of the combination.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x